Holding(s) in Company
Northern Standard Limited has notified Thalia Therapeutics plc of a change in its major holding, with its voting rights decreasing from 18.02% to 16.66% following participation in a fundraising and subsequent dilution after an acquisition for shares completed on July 18, 2026. This resulted in Northern Standard Limited holding 295,833,333 voting rights. The notification also clarifies that while Mr. Edward James Norman Wardle owns 49% of Northern Standard Limited, he does not exercise majority control, with Dr. John Wardle, through Tracarta Limited, holding the controlling 51% stake.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
UK
- Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
| Other (please specify) iii : Participation in fundraising and subsequent dilution following an acquisition for shares which completed on 18 July 2026 | x |
Details of person subject to the notification obligation iv
| Name | Northern Standard Limited |
| City and country of registered office (if applicable) | 2 nd Floor, Connaught House, St. Julian's Avenue, St. Peter Port, Guernsey, GY1 1GZ |
Full name of shareholder(s) (if different from 3.) v
| Name | Fiske Nominees Limited |
| City and country of registered office (if applicable) | 100 Wood Street, London, England, EC2V 7AN |
| 5. Date on which the threshold was crossed or reached vi : | 18 July 2026 |
| 6. Date on which issuer notified (DD/MM/YYYY): | 27 July 2026 |
- Total positions of person(s) subject to the notification obligation
| Resulting situation on the date on which threshold was crossed or reached | 16.66 | - | 16.66 | 295,833,333 |
| Position of previous notification (if applicable) | 18.02 | - | 18.02 | |
| A: Voting rights attached to shares | ||||
| Class/type of shares ISIN code (if possible) | Number of voting rights ix | % of voting rights | ||
| Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | |
| GB00BYW8QM32 | 295,833,333 | - | 16.66 | - |
| SUBTOTAL 8. A | 295,833,333 | 16.66 | ||
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
SUBTOTAL 8.B.2
| Northern Standard Limited | 16.66 | - | 16.66 |
In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
- Additional information xvi
- Edward James Norman Wardle, who is a non-executive director of Thalia Therapeutics Plc, holds a 49% ownership interest in Northern Standard Limited but does not exercise majority control. The chain of control is through Dr John Wardle, who owns 100% of Tracarta Limited, which holds 51% of Northern Standard Limited.
| Place of completion | St. Peter Port, Guernsey |
| Date of completion | 18 July 2026 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.